Diabetes, subclinical myocardial injury or stress and risk of heart failure subtypes: the Jackson Heart study
Kaze AD, Bertoni AG, Fox ER, et al.
Diabetes Care. 2025:dc240654.
Leggi
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials
Rubino DM, Pedersen SD, Connery L, et al.
Diabetes Obes Metab. Pub. online 9 Jan 2025.
Leggi
Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1-5 clinical trials
Apperloo EM, Tuttle KR, Pavo I, et al.
Diabetes Care. 2025:dc241773.
Leggi
Prescribing trends of antidiabetes medications near end-of-life among adults with type 2 diabetes: a cohort study
Kutz A, Kim DH, Liu J, et al.
Diabetes Care. 2025:dc241795.
Leggi
Machine learning techniques to predict diabetic ketoacidosis and HbA1c >7% among individuals with type 1 diabetes- a large multi-centre study in Australia & New Zealand
Earnest A, Jones TW, Chee M, et al.
Nutr Metab Cardiovasc Dis. Pub. online 8 Jan 2025.
Leggi
OCCHIO AL TRIAL: SELECT – 23 GENNAIO 2025, ORE 18
Carissimi Soci, primo appuntamento 2025 con la nuova iniziativa AMD Occhio al Trial. Ci troveremo il 23 gennaio, alle ore 18, per un approfondimento sulle Nuove evidenze dal SELECT: efficacia nel lungo termine di semaglutide nel mantenimento del calo ponderale descritto e commentato dalla dott.ssa Laura Molteni e dal dott. Andrea Di Lenarda. Qui il link…
Leggi
Oral glucose-lowering agents vs insulin for gestational diabetes: a randomized clinical trial
Rademaker D, de Wit L, Duijnhoven RG, et al.
JAMA. Pub. online 6 Jan 2025.
Leggi
Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: current clinical landscape and perspectives
Podobnik J, Prentice KJ
Diabetes Obes Metab. Pub. online 6 Jan 2025.
Leggi
Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): a population-based cohort study
Hopkins R, Young KG, Thomas NJ, et al.
Diabetes Obes Metab. Pub. online 6 Jan 2025.
Leggi
Long-term cognitive safety of achieving very low LDL cholesterol with evolocumab
Zimerman A, O’Donoghue ML, Ran X, et al.
NEJM Evid. 2025;4(1):EVIDoa2400112.
Leggi